ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1375	National Cancer Institute	Html	en	Cancer Screening Overview (PDQ®)–Health Professional Version	Information about measuring the effectiveness of cancer screening tests and about weighing the strength of the evidence obtained from cancer screening research studies.	PDQ Screening 0.435302 cancer antigen 0.351044 cancer screening interventions 0.511292 advanced-stage pancreatic cancer 0.361147 cancer screening 0.938139 lung cancer screening 0.519031 new screening test 0.500274 cancer prevention 0.350991 Interval cancer events 0.364348 new screening modality 0.453389 IIIB–IV lung cancer 0.361117 prostate screening 0.417963 lung cancer rates 0.355466 prostate cancer treatment 0.3549 mammography screening 0.457867 screening program 0.415447 screening summaries 0.435473 disease-specific mortality 0.409334 cancer cases 0.346604 whole-body screening technologies 0.500642 lower cancer risk 0.359738 interval cancer rates 0.358328 colorectal cancer 0.351483 routine cancer screening 0.555956	recent screening 0.436851 false-negative screening test 0.511207 older screening modalities 0.448481 breast cancer 0.418358 cancer diagnosis 0.374736 prostate cancer screening 0.551218 actual cancer risk 0.422669 cancer screening tests 0.659235 randomized controlled trial 0.36573 prostate cancer mortality. 0.348853 false-positive screening results 0.509129 screening center 0.444606 fecal occult blood 0.356414 higher cancer risk 0.360321 cancer mortality. 0.353113 decision making 0.410621 all-cause mortality 0.362129 breast cancer overdetection 0.35093 routine screening mammographies 0.474709 randomized clinical trials 0.34952 Cancer Screening Trial 0.566983 invasive diagnostic procedures 0.355819 routine PSA screening 0.472621	CLICK HERE
1456	National Cancer Institute	Html	en	Vulvar Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of vulvar cancer.	lesion-type VIN grade 0.488217 radiation therapy arm 0.777718 vulvar surgical procedures 0.466679 sentinel node dissection 0.727156 Radiation Therapy section 0.586061 case series 0.468674 groin dissection study 0.616489 vulvar cancer 0.538035 positive sentinel nodes 0.479331 lymph node dissection 0.680638 sentinel node identification. 0.538816 invasive vulvar cancer 0.471336 vulvar cancer-related deaths 0.462293 radiation therapy issue 0.483522 clinically localized vulvar 0.482117 node dissection 0.932807 bloc inguinal node 0.506403 sentinel node dissections 0.642236 bilateral groin node 0.587002 Actuarial groin recurrence 0.544605 groin lymph 0.484094 pelvic node resection 0.498834 radical vulvectomy 0.489162 sentinel node 0.79935	high-grade vin 0.507503 bilateral dissection 0.465866 groin dissection arm 0.620835 invasive locoregional vulvar 0.48636 sentinel node procedures 0.539343 groin recurrence 0.545931 groin dissection 0.6467 femoral lymph node 0.521493 negative sentinel node 0.528158 negative sentinel nodes 0.475577 patients 0.605395 groin-node dissection 0.464 inguinal node dissection 0.663124 groin node dissection 0.784008 ipsilateral inguinal node 0.504912 pelvic radiation 0.458909 Node metastases 0.461128 groin node-positive disease 0.523738 groin radiation 0.532254 regional lymph nodes 0.463891 HPV 6/11-associated vulvar 0.461386 negative groin nodes 0.546977 systematic literature review 0.508112	CLICK HERE
1518	National Cancer Institute	Html	en	Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma.	indolent lymphoma 0.464365 treatment 0.544599 monocytoid B-cell lymphoma 0.420859 plasmablastic lymphoma 0.419927 NK -/T-cell lymphoma 0.426757 small lymphocytic lymphoma 0.423228 gastric malt lymphoma 0.422838 Immunodeficiency-related Burkitt lymphoma 0.415337 aggressive non-Hodgkin lymphoma 0.475259 cutaneous T-cell lymphoma 0.428401 panniculitis-like T-cell lymphoma 0.426066 Non-Hodgkin Lymphoma section 0.42959 extranodal nk-/t-cell lymphoma 0.422171 intestinal T-cell lymphoma 0.425153 cancer cells 0.415937 burkitt lymphoma 0.478875 type 0.432175 Childhood Non-Hodgkin Lymphoma 0.486001 Non-Hodgkin Lymphoma Treatment 0.517724 non-Hodgkin lymphoma depend 0.431176 B-cell non-Hodgkin lymphoma 0.483095 adult non-hodgkin lymphoma 0.682631 Hepatosplenic T-cell lymphoma 0.418177 mantle cell lymphoma 0.469654	clinical trials 0.431842 large cell lymphoma 0.519814 peripheral t-cell lymphoma 0.449001 lymphoblastic lymphoma 0.466951 sporadic Burkitt lymphoma 0.415034 follicular lymphoma 0.466223 lymphoplasmacytic lymphoma 0.484976 anaplastic lymphoma kinase 0.415433 zone lymphoma forms 0.432298 extragastric malt lymphoma 0.451025 non-hodgkin lymphoma 0.940013 bone marrow 0.479363 Mediterranean abdominal lymphoma 0.426917 marginal zone lymphoma 0.520209 aggressive lymphoma 0.473801 lymphoma cells 0.457101 Angioimmunoblastic T-cell lymphoma 0.41858 lymph nodes 0.489794 large B-cell lymphoma 0.570397 radiation therapy 0.436362 anaplastic large cell 0.422021 cancer 0.555203 indolent non-hodgkin lymphoma 0.488068	CLICK HERE
1553	National Cancer Institute	Html	en	Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.	cancer treatment 0.41722 Burkitt-like non-Hodgkin lymphoma 0.414505 panniculitis-like T-cell lymphoma 0.407586 mediastinal B-cell lymphoma 0.477834 type 0.421123 body 0.397298 childhood non-hodgkin lymphoma 0.888605 PDQ cancer information 0.389516 Non-Hodgkin Lymphoma Treatment 0.431482 clinical trial search 0.395907 B-cell non-Hodgkin lymphoma 0.444319 gamma-delta T-cell lymphoma 0.40789 clinical trials 0.596027 large cell lymphoma 0.576342 peripheral t-cell lymphoma 0.4403 clinical trial 0.545942 stem cell transplant 0.416614 Burkitt lymphoma 0.412037 anaplastic lymphoma kinase 0.405034 primary mediastinal b-cell 0.402494 diffuse large b-cell 0.419339 lymph nodes 0.504405 Pediatric-type follicular lymphoma 0.401311 large B-cell lymphoma 0.505692	radiation therapy 0.400696 childhood hodgkin lymphoma 0.422956 treatment 0.602592 Hodgkin Lymphoma Treatment 0.428936 cutaneous t-cell lymphoma 0.531706 cancer cells 0.482982 Burkitt-like lymphoma /leukemia 0.41493 HIV-related non-Hodgkin lymphoma 0.410943 certain gene changes 0.416336 Adult Non-Hodgkin Lymphoma 0.452762 recurrent lymphoblastic lymphoma 0.388804 lymphoblastic lymphoma 0.418163 follicular lymphoma 0.416701 combination chemotherapy 0.479578 non-hodgkin lymphoma 0.995932 bone marrow 0.469909 marginal zone lymphoma 0.455485 cells 0.53075 cancer clinical trials 0.407298 lymph node 0.390457 treatment options 0.51667 anaplastic large cell 0.523091 HIV-associated non-Hodgkin lymphoma 0.431952 cancer 0.673011	CLICK HERE
1706	National Cancer Institute	Html	en	Tumor Markers	A fact sheet that defines tumor markers and describes how they can be used to aid diagnosis and treatment.	average risk 0.450619 Urokinase plasminogen activator 0.459684 EGFR gene mutation 0.458827 low recurrence rates 0.462003 potential markers 0.487538 tumor marker 0.811954 Laboratory Improvement Amendments 0.454191 Cancer researchers 0.453927 tumor tissue 0.581622 prostate cancer deaths 0.482408 cancer cells 0.464646 randomized controlled trials 0.451211 cancer therapy 0.462023 Programmed death ligand 0.453669 certain tumor markers 0.637279 Tumor marker levels 0.59758 tumor cells 0.533609 hormone therapy 0.468386 plasminogen activator inhibitor 0.458435 Ovarian Cancer Screening 0.481982 oncotype dx® 0.458204 NCI-sponsored Trial Assigning 0.453214 cancer care 0.460826 European Randomized Study 0.452179	benign prostate conditions 0.461678 BRAF V600 mutations 0.455095 tumor markers 0.944185 ovarian cancer 0.509174 gene mutation 0.459648 Diagnosis research page 0.451878 cancer types 0.497466 BCR-ABL fusion gene 0.458705 follow-up diagnostic tests 0.453464 Beta-human chorionic gonadotropin 0.457581 prostate cancer 0.504684 KRAS gene mutation 0.459458 elevated PSA level 0.472298 ALK gene rearrangements 0.462612 cancer staging 0.458494 accurate tumor markers 0.611174 cancer recurrence 0.463465 different tumor markers 0.654628 HER2-negative breast cancer 0.476048 noncancerous) conditions. 0.470899 cancer 0.625548 Nuclear matrix protein 0.450815 gene expression 0.46063	CLICK HERE
1836	National Cancer Institute	Html	es	Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mieloide aguda infantil, síndromes mielodisplásicos y otras neoplasias mieloproliferativas.	frecuencia mutaciones 0.438095 LMA familiares 0.551304 leucemia eritroidea aguda 0.449843 American Academy 0.418016 Leucemia aguda eritroidea 0.453243 gen runx1t1 0.417024 neoplasias mieloides 0.421266 transient leukemia 0.421355 Sin embargo 0.442991 gen crebbp 0.417273 LMA ayuda 0.492779 necesarias mutaciones 0.436351 leucemia mielomonocítica aguda 0.45265 Panmielosis aguda 0.424398 subtipo fab 0.419671 leucemias mieloides 0.437133 Leucemia basofílica aguda 0.453074 leucemia mielógena 0.434701 Children's Oncology Group 0.430324 gen etv6 0.41685 leucemia transitoria 0.433759 reordenamiento leucemia aguda 0.452795 Leucemia megacarioblástica aguda 0.453115 Smith MA 0.431884 Leucemia aguda mielomonocítica 0.453529	gen evi1 0.417889 leucemia promielocítica aguda 0.56535 Organización Mundial 0.42957 gen mll 0.697325 células madre 0.41719 leucemia aguda 0.953312 LMA M0 0.546818 leucemia linfoblástica aguda 0.491741 SAI Leucemia 0.451225 tipo ii 0.459931 gen runx1 0.418208 Pediatr Blood Cancer 0.433879 gen cbf-beta 0.418127 M0 LMA 0.495335 leucemia monocítica aguda 0.501087 fraterno presente leucemia 0.436812 linaje mieloide 0.448127 leucemias bifenotípicas mieloides 0.422616 leucemia megacariocítica aguda 0.525006 leucemia mieloblástica aguda 0.537614 BCR-ABL1 Leucemia aguda 0.451622 leucemia mieloide aguda 0.756372 linaje linfoide 0.423692 La traslocación 0.522981	CLICK HERE
2024	National Cancer Institute	Html	es	Exámenes de detección del cáncer de seno (mama) (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre exámenes que se usan para detectar el cáncer de mama.	siguientes grupos 0.672278 antecedentes familiares 0.758929 riesgo promedio 0.654596 mamas ayuda 0.659647 siguientes aspectos 0.90581 PDQ Exámenes 0.70298 científicos estudian 0.803132 Physician Data Query 0.762154 Estados Unidos 0.676822 Cuánto dolor 0.645226 siguientes características 0.695745 rayos x 0.663809	prevención revisa 0.628149 PDQ Prevención 0.818992 presente síntomas 0.647624 información ayuda 0.645226 National Cancer Institute 0.638447 mamografía dé 0.72651 siguientes riesgos 0.642827 PDQ Aspectos 0.696695 genes brca1 0.6651 siguientes sumarios 0.787128 Instituto Nacional 0.674216	CLICK HERE
2046	National Cancer Institute	Html	es	Exámenes de detección del cáncer de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de ovario, de trompas de Falopio y primario de peritoneo.	sumario prevención 0.472534 Visuals Online 0.345966 PDQ Exámenes 0.447043 Physician Data Query 0.632388 Gynecologic Cancers 0.420191 Estados Unidos 0.412228 cuello uterino 0.924963 prevención revisa 0.358425 principal causa 0.399054	uso conjunto 0.372607 información ayuda 0.370212 Características genéticas 0.409802 National Cancer Institute 0.381425 ecografía transvaginal 0.909246 siguientes riesgos 0.361332 siguientes sumarios 0.506181 Instituto Nacional 0.45524	CLICK HERE
4329	National Cancer Institute	Html	en	Cancer Screening	A summary of the benefits and possible harms of cancer screening tests.	time symptoms 0.320649 abnormal tissue 0.346264 False-negative test results 0.440391 screening tests 0.953871 false reassurance 0.328265 potential harms 0.743558 different cancer screening 0.573019 medical care 0.312433	people 0.200595 Early detection 0.319119 additional tests 0.299571 health problems 0.324983 doctors 0.208104 False-positive test results 0.450006 cancer 0.861445	CLICK HERE
14600	National Cancer Institute	Html	es	Tratamiento de los tumores vasculares infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores vasculares infantiles.	Natl Acad Sci 0.324634 anomalías vasculares retinianas 0.33309 hemangiomas is directly 0.365854 lesiones benignas 0.319493 Infants With Infantile 0.316042 lesiones precursoras 0.322133 frecuencia cardíaca 0.363288 cells from hemangiomas 0.365897 Denise Adams 0.34719 Ampliar Figura 0.334799 hemangiomas perioculares subcutáneos 0.383239 propranolol quizás 0.334782 Prospective study 0.315057 capillary hemangioma 0.369091 International Society 0.348608 vasculares hepáticos benignos 0.326723 tumores vasculares benignos 0.402681 Léauté-Labrèze C 0.314686 evaluación cardíaca 0.323474 angiofibromas nasofaríngeos 0.342724 síndrome phace 0.577507 angiofibroma nasofaríngeo 0.314735 anomalías renales 0.316886 Children With Infantile 0.315749 oral propranolol 0.362065	Clin Invest 0.327186 hemangiomas congénitos 0.761656 endothelial cells 0.315693 hemangiomas cutáneos 0.372477 Arch Dermatol 0.329954 Cuadro clínico 0.393896 Proc Natl Acad 0.325302 infantile hemangiomas 0.938164 With Infantile Hemangioma 0.438965 Nadolol Versus Propranolol 0.33549 vías respiratorias 0.521847 granuloma piógeno 0.329351 Vascular Anomalies Classification 0.319289 insuficiencia cardíaca transitoria 0.335633 antecedentes familiares 0.32937 hemangioma cutáneo congénito 0.383839 Complicated Vascular Anomalies 0.316136 Benigno Hemangioma 0.393265 Drolet BA 0.324986 lesiones cutáneas 0.338858 clasificación issva 0.316546 Blei F 0.314967 hemangioma epitelioide 0.552561 Hoeger P 0.315823	CLICK HERE